GB0220953D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0220953D0
GB0220953D0 GBGB0220953.4A GB0220953A GB0220953D0 GB 0220953 D0 GB0220953 D0 GB 0220953D0 GB 0220953 A GB0220953 A GB 0220953A GB 0220953 D0 GB0220953 D0 GB 0220953D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0220953.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0220953.4A priority Critical patent/GB0220953D0/en
Publication of GB0220953D0 publication Critical patent/GB0220953D0/en
Priority to BR0314164-0A priority patent/BR0314164A/pt
Priority to CNA038212552A priority patent/CN1681803A/zh
Priority to EP03755553A priority patent/EP1539737A1/en
Priority to US10/527,518 priority patent/US7678814B2/en
Priority to AU2003273398A priority patent/AU2003273398A1/en
Priority to JP2004535464A priority patent/JP4564846B2/ja
Priority to CA2498285A priority patent/CA2498285C/en
Priority to PCT/EP2003/010007 priority patent/WO2004024714A1/en
Priority to US12/690,210 priority patent/US8193218B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0220953.4A 2002-09-10 2002-09-10 Organic compounds Ceased GB0220953D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0220953.4A GB0220953D0 (en) 2002-09-10 2002-09-10 Organic compounds
PCT/EP2003/010007 WO2004024714A1 (en) 2002-09-10 2003-09-09 Aroyl-piperidine derivatives
US10/527,518 US7678814B2 (en) 2002-09-10 2003-09-09 Aroyl-piperidine derivatives
CNA038212552A CN1681803A (zh) 2002-09-10 2003-09-09 芳酰基－哌啶衍生物
EP03755553A EP1539737A1 (en) 2002-09-10 2003-09-09 Aroyl-piperidine derivatives
BR0314164-0A BR0314164A (pt) 2002-09-10 2003-09-09 Derivados de aroil-piperidina
AU2003273398A AU2003273398A1 (en) 2002-09-10 2003-09-09 Aroyl-piperidine derivatives
JP2004535464A JP4564846B2 (ja) 2002-09-10 2003-09-09 アロイル−ピペリジン誘導体
CA2498285A CA2498285C (en) 2002-09-10 2003-09-09 Aroyl-piperidine derivatives
US12/690,210 US8193218B2 (en) 2002-09-10 2010-01-20 Aroyl-piperidine derivatives and method of treating disorders induced by substance P

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0220953.4A GB0220953D0 (en) 2002-09-10 2002-09-10 Organic compounds

Publications (1)

Publication Number Publication Date
GB0220953D0 true GB0220953D0 (en) 2002-10-23

Family

ID=9943781

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0220953.4A Ceased GB0220953D0 (en) 2002-09-10 2002-09-10 Organic compounds

Country Status (9)

Country Link
US (2) US7678814B2 (https=)
EP (1) EP1539737A1 (https=)
JP (1) JP4564846B2 (https=)
CN (1) CN1681803A (https=)
AU (1) AU2003273398A1 (https=)
BR (1) BR0314164A (https=)
CA (1) CA2498285C (https=)
GB (1) GB0220953D0 (https=)
WO (1) WO2004024714A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
CN101668527A (zh) * 2007-02-23 2010-03-10 阿韦拉制药股份有限公司 药物制剂
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6115A (ja) * 1984-06-12 1986-01-06 Kyowa Hakko Kogyo Co Ltd リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
TW397825B (en) 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
TW475930B (en) 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
AU2898297A (en) 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
AR018376A1 (es) 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
JP4510290B2 (ja) 1998-08-25 2010-07-21 ノバルティス アーゲー 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用
KR20030027016A (ko) * 2000-08-09 2003-04-03 에프. 호프만-라 로슈 아게 항-염증제로서의 퀴놀린 유도체
JP2002220386A (ja) * 2000-10-02 2002-08-09 Tanabe Seiyaku Co Ltd ベンジルアミン誘導体、その製法およびその合成中間体
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2498285C (en) 2011-07-26
CA2498285A1 (en) 2004-03-25
US7678814B2 (en) 2010-03-16
US20100120852A1 (en) 2010-05-13
JP4564846B2 (ja) 2010-10-20
US20060135558A1 (en) 2006-06-22
WO2004024714A1 (en) 2004-03-25
US8193218B2 (en) 2012-06-05
EP1539737A1 (en) 2005-06-15
BR0314164A (pt) 2005-07-19
AU2003273398A1 (en) 2004-04-30
JP2006502171A (ja) 2006-01-19
CN1681803A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
GB0203276D0 (en) Organic compounds
GB0202873D0 (en) Organic compounds
GB0205281D0 (en) Organic compounds
EG23462A (en) Organic compounds
GB0209481D0 (en) Organic compounds
GB0220953D0 (en) Organic compounds
GB0203061D0 (en) Organic compounds
GB0202874D0 (en) Organic compounds
GB0211261D0 (en) Organic compounds
GB0204756D0 (en) Organic compounds
GB0210535D0 (en) Organic compounds
GB0209257D0 (en) Organic compounds
GB0205537D0 (en) Organic compounds
GB0207499D0 (en) Organic compounds
GB0202875D0 (en) Organic compounds
GB0204752D0 (en) Organic compounds
GB0204754D0 (en) Organic compounds
GB0202755D0 (en) Organic compounds
GB0204763D0 (en) Organic compounds
GB0204765D0 (en) Organic compounds
GB0204766D0 (en) Organic compounds
GB0205023D0 (en) Organic compounds
GB0205280D0 (en) Organic compounds
GB0202381D0 (en) Organic compounds
GB0209889D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)